Literature DB >> 6992318

Studies on the effects of cyclosporin A upon renal allograft rejection in the dog.

W P Homan, M E French, P Millard, T G Denton, J W Fabre, P J Morris.   

Abstract

Dose and time response studies of the new immunosuppressive agent, cyclosporin A, have been performed in a dog renal allograft model. Rejection of a renal allograft only occurred in one of six dogs receiving 20 mg/kg/day continuously, but in 10 of 11 dogs receiving 10 mg/kg/day. Doses of 10 or 20 mg/kg/day given for 2 or 3 weeks delayed rejection, but rejection occurred in all animals when the drug was stopped. This suggests that the drug does not produce clonal deletion of the lymphocytes engaged in the immune reaction against the graft, but merely their suppression. The histological picture of rejection was markedly improved by therapeutic doses of cyclosporin A. No consistent histological or biochemical evidence for heptatoxicity or nephrotoxicity was found even in the higher doses tested. One fatal and four non-fatal infectious complications were seen in 29 dogs receiving doses of 5 mg/kg/day or higher.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6992318

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  General surgery-epitomes of progress: modern era of kidney transplantation.

Authors:  S N Chatterjee
Journal:  West J Med       Date:  1980-12

2.  Experimental vascularized segmental pancreatic and islet transplantation in the baboon.

Authors:  D F du Toit; J J Heydenrych; B Smit; G Louw; T Zuurmond; L Laker; D Els; A Weideman; S Wolfe-Coote; E A van der Merwe
Journal:  World J Surg       Date:  1984-04       Impact factor: 3.352

3.  Cyclosporine in the treatment of steroid resistant rejection episodes in living donor kidney transplants.

Authors:  M Sobh; F el-Husseini; A Shebab el-Din; M Ghoneim
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

4.  Preclinical systematic review & meta-analysis of cyclosporine for the treatment of myocardial ischemia-reperfusion injury.

Authors:  Joshua Hefler; Braulio A Marfil-Garza; Sandra Campbell; Darren H Freed; A M James Shapiro
Journal:  Ann Transl Med       Date:  2022-09

5.  Mechanism of recovery from acute virus infection. II. Effect of treatment of mice with cyclosporin A on their ability to eliminate the lymphocytic choriomeningitis virus.

Authors:  C Löliger; F Lehmann-Grube
Journal:  Med Microbiol Immunol       Date:  1985       Impact factor: 3.402

6.  Cyclosporin A: a powerful immunosuppressant.

Authors:  A Laupacis; P A Keown; R A Ulan; N McKenzie; C R Stiller
Journal:  Can Med Assoc J       Date:  1982-05-01       Impact factor: 8.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.